| The therapeutic journey of benzimidazoles: A review Y Bansal, O Silakari Bioorganic & medicinal chemistry 20 (21), 6208-6236, 2012 | 965 | 2012 |
| Flavones: An important scaffold for medicinal chemistry M Singh, M Kaur, O Silakari European journal of medicinal chemistry 84, 206-239, 2014 | 603 | 2014 |
| Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view N Chadha, O Silakari European Journal of Medicinal Chemistry 134, 159-184, 2017 | 570 | 2017 |
| Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection M Singh, M Kaur, H Kukreja, R Chugh, O Silakari, D Singh European journal of medicinal chemistry 70, 165-188, 2013 | 412 | 2013 |
| Coumarin hybrids as novel therapeutic agents S Sandhu, Y Bansal, O Silakari, G Bansal Bioorganic & medicinal chemistry 22 (15), 3806-3814, 2014 | 343 | 2014 |
| Oxindole: A chemical prism carrying plethora of therapeutic benefits M Kaur, M Singh, N Chadha, O Silakari European Journal of Medicinal Chemistry 123, 858-894, 2016 | 282 | 2016 |
| Multifunctional compounds: Smart molecules for multifactorial diseases Y Bansal, O Silakari European Journal of Medicinal Chemistry 76, 31-42, 2014 | 263 | 2014 |
| The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options S Choudhary, K Sharma, O Silakari Microbial Pathogenesis, 104673, 2020 | 195 | 2020 |
| Thiazolidine-2, 4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions N Chadha, MS Bahia, M Kaur, O Silakari Bioorganic & Medicinal Chemistry 23 (13), 2953-2974, 2015 | 120 | 2015 |
| Purinergic receptor P2X7: a novel target for anti-inflammatory therapy N Mehta, M Kaur, M Singh, S Chand, B Vyas, P Silakari, MS Bahia, ... Bioorganic & medicinal chemistry 22 (1), 54-88, 2014 | 115 | 2014 |
| Benzimidazole derivatives: search for GI-friendly anti-inflammatory analgesic agents M Gaba, P Gaba, D Uppal, N Dhingra, MS Bahia, O Silakari, C Mohan Acta Pharmaceutica Sinica B 5 (4), 337-342, 2015 | 98 | 2015 |
| Hybrids: a new paradigm to treat Alzheimer’s disease M Singh, M Kaur, N Chadha, O Silakari Molecular diversity 20, 271-297, 2016 | 96 | 2016 |
| The current status of O‐heterocycles: A synthetic and medicinal overview PK Singh, O Silakari ChemMedChem 13 (11), 1071-1087, 2018 | 89 | 2018 |
| Success stories of natural product-based hybrid molecules for multi-factorial diseases S Choudhary, PK Singh, H Verma, H Singh, O Silakari European journal of medicinal chemistry 151, 62-97, 2018 | 84 | 2018 |
| Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications A Kumari, O Silakari, RK Singh Biomedicine & Pharmacotherapy 103, 662-679, 2018 | 83 | 2018 |
| Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review M Arora, S Choudhary, PK Singh, B Sapra, O Silakari Life sciences 251, 117631, 2020 | 72 | 2020 |
| Key heterocycle cores for designing multitargeting molecules O Silakari Elsevier, 2018 | 71 | 2018 |
| Exploration of the therapeutic aspects of Lck: A kinase target in inflammatory mediated pathological conditions PK Singh, A Kashyap, O Silakari Biomedicine & Pharmacotherapy 108, 1565-1571, 2018 | 67 | 2018 |
| An update on small molecule strategies targeting leishmaniasis S Kapil, PK Singh, OM Silakari European journal of medicinal chemistry 157, 339-367, 2018 | 66 | 2018 |
| Inhibitors of switch kinase ‘spleen tyrosine kinase’in inflammation and immune-mediated disorders: a review M Kaur, M Singh, O Silakari European journal of medicinal chemistry 67, 434-446, 2013 | 65 | 2013 |
